Canaccord analyst Arlinda Lee lowered her price target on Ultragenyx to $75 from $90, citing the announced discontinuation of triheptanoin development, which she removed from her model. Lee reiterated her Buy rating on Ultragenyx shares, noting its first commercial launches of Crysvita and Mepsevil are under way.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.